The Ipsen Investment Case
Conclusion
Executing in line with our strategy
Delivery
of strong 2021 results
Top-line growth across all core
and innovative brands
An expanded
core operating margin
Sound financial structure and
strong cash generation
€
Clinical
development milestones
Cabometyx atezolizumab:
2L NSCLC Phase III data readout
Onivyde: 2L SCLC
Phase III data readout
Palovarotene: FOP
regulatory resubmission
Mesdopetam: PD-LID
Phase IIb data readout
Business
development opportunities
Seven transactions in 2021
External innovation:
the primary capital-allocation
priority, underpinned by a
strong financial position
Across the three
therapeutic areas
Strengthened capacity and
firepower to execute further
IPSEN
Innovation for patient care
19View entire presentation